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Artilysins constitute a novel class of efficient enzyme-based antibacterials. Specifically, they covalently combine a bacteriophage-
encoded endolysin, which degrades the peptidoglycan, with a targeting peptide that transports the endolysin through the outer
membrane of Gram-negative bacteria. Art-085, as well as Art-175, its optimized homolog with increased thermostability, are
each composed of the sheep myeloid 29-amino acid (SMAP-29) peptide fused to the KZ144 endolysin. In contrast to KZ144, Art-
085 and Art-175 pass the outer membrane and kill Pseudomonas aeruginosa, including multidrug-resistant strains, in a rapid
and efficient (5 log units) manner. Time-lapse microscopy confirms that Art-175 punctures the peptidoglycan layer within 1
min, inducing a bulging membrane and complete lysis. Art-175 is highly refractory to resistance development by naturally oc-
curring mutations. In addition, the resistance mechanisms against 21 therapeutically used antibiotics do not show cross-resis-
tance to Art-175. Since Art-175 does not require an active metabolism for its activity, it has a superior bactericidal effect against
P. aeruginosa persisters (up to>4 log units compared to that of the untreated controls). In summary, Art-175 is a novel antibac-
terial that is well suited for a broad range of applications in hygiene and veterinary and humanmedicine, with a unique potential
to target persister-driven chronic infections.
During the so-called golden age of antibiotics in the 1960s,many thought the war against bacterial infections was
won, but this confidence was proven to be premature. More
than ever, the increasing emergence of multidrug-resistant
bacterial infections and a drying pipeline of new antibiotics call
for the development of novel classes of antibiotics and new
antibacterial strategies that can help address this global health
care threat (1). However, only four new classes of antibiotics
have been approved to the market in the last decade: (i) oxazo-
lidones (linezolid), (ii) lipopeptides (daptomycin), (iii) pleu-
romutilins (retapamulin), and (iv) macrocycles (fidaxomicin).
All of these target Gram-positive infections, and none of these
drugs have novel mechanisms of action (2). In fact, these four
chemical classes were all reported or patented prior to 1987,
and no novel classes have been discovered since then. Hence, the
discovery void is without precedent (3, 4). Governmental incen-
tives, like the New Drugs 4 Bad Bugs (ND4BB) program, a core
element of the European public-private InnovativeMedicines Ini-
tiative, and the Generating Antibiotic Incentives Now (GAIN) act
of the FDA further underline this alarming situation. The overuse
of antibiotics in medicine (50% of all antibiotics prescribed for
people are not needed or not optimally effective [5]) and the mis-
use for nonmedical purposes as growth promoters in livestock and
poultry have now been addressed by European Union legislation
(6) andU.S. FDA guidelines (see the FDA’s strategy on antimicro-
bial resistance [http://www.fda.gov/animalveterinary
/guidancecomplianceenforcement/guidanceforindustry/ucm216
939.htm]).
Among all resistant pathogens, the situation is most critical for
Gram-negative pathogens, which often show more extensive re-
sistance to the available therapeutic options than do Gram-posi-
tive pathogens. One of the prevailing reasons is the presence of the
protective outer membrane in Gram-negative pathogens, which
represents a formidable barrier for antibiotics to overcome (7, 8).
This not only eliminates the susceptibility of Gram-negative
pathogens to many existing antibiotics, but also means that the
current development pipeline of novel antibiotics has been di-
rected toward resistant Gram-positive pathogens, such as methi-
cillin-resistant Staphylococcus aureus (MRSA). Therefore, the
difficulty in discovering new antibiotics that are active against
Gram-negative species is not a paucity of targets per se, but rather
lies in the impermeability of the outer membrane (3). Persisters,
an antibiotic-tolerant subpopulation, pose an additional chal-
lenge. They are proposed to be the cause of the rising number of
chronic infections, simply because surviving persisters may re-
populate the infection site once the periodic application of antibi-
otics stops (8). Therefore, novel effective drugs against persisters
are of utmost importance.
The introduction of bacterial genome sequencing heralded a
new era of hope for antibiotic discovery. However, the genomics
approach for delivering novel targets for traditional small-mole-
cule screening yielded a disappointing and financially unsustain-
able outcome (2, 9). Alternative antibacterial approaches, such as
those involving cationic antimicrobial peptides and endolysins,
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emerged and are highly promising routes of investigation for con-
trolling antibiotic-resistant bacteria (10–12).
Antimicrobial peptides are produced by a wide variety of or-
ganisms in the animal and plant kingdoms, and they play a fun-
damental role in nonspecific innate immunity. Although diverse
with respect to their amino acid sequences, they share an amphi-
pathic conformation, with positively charged amino acids distrib-
uted on one side and hydrophobic amino acids on the other side
(13). The overall positive charge of these peptides allows them to
accumulate at the polyanionic cell surface, which contains acidic
polymers, such as lipopolysaccharide (LPS) and teichoic acids, in
Gram-negative and Gram-positive bacteria, respectively (10). In
Gram-negative bacteria, the peptides pass the outermembrane via
a self-promoted uptake pathway: first, they interact with the cat-
ion binding sites of LPSmolecules by competitive displacement of
the divalent cations Mg2 or Ca2, and then they disrupt the
barrier function of themembrane due to their bulkiness; transient
cracks in the LPS layer subsequently permit uptake not only of
themselves but also of other antibiotics or small proteins (14). The
peptides kill the bacterium by either disrupting the cytoplasmic
membrane or by crossing this membrane and acting on intracel-
lular targets (10). Unfortunately, such peptides are often associ-
ated with cytotoxic properties (15).
Endolysins are enzymes produced by bacterial viruses (bacte-
riophages) at the end of their lytic cycle. They enzymatically de-
grade the peptidoglycan (PG) layer, the major structural compo-
nent of a bacterium, from within the infected host cell. As such,
they induce a sudden lysis of the infected bacterial cell in order to
dissipate the newly formed phage particles (16). Exogenous appli-
cation of purified endolysins to Gram-positive pathogens quickly
kills them by lysis due to turgor pressure. Their efficacy as anti-
bacterials has been shown for the treatment of mucosal and sys-
temic Gram-positive infections in diverse animal models and for
food applications (for reviews, see references 17 to 19). No resis-
tant strains have been isolated so far in spite of a number of at-
tempts to elicit resistance to endolysins against Gram-positive
bacteria (20–22). The specificity of an endolysin in general is de-
termined by the susceptibility of a certain PG chemotype for the
enzymatically active domain (EAD) and the recognition of the cell
wall or associated ligand by the cell wall binding domain (CBD),
limiting the antibacterial effect to a certain genus, species, serovar,
or strain (12, 18).
A major hurdle in the development of endolysins as antibacte-
rials is the expansion to Gram-negative pathogens, since the outer
membrane shields access to the PG fromoutside. This has partially
been overcome by combining endolysins with outer membrane-
permeabilizing agents, like EDTA (23). In this study,we combined
the self-promoted uptake mechanism of a cationic antimicrobial
peptide and the PG-degrading activity of an endolysin to tackle
this hurdle. Specifically, we fused the sheepmyeloid antimicrobial
peptide of 29 amino acids (SMAP-29) (24) to the N terminus of
the endolysin KZ144 (25) to create a so-called Artilysin. SMAP-29
is an -helical cathelicidin found in sheep leukocytes and pos-
sesses potent antimicrobial activity against a broad spectrum of
pathogens, including Pseudomonas aeruginosa, the target in this
study. SMAP-29 is amphipathic and has two LPS binding sites
(26). KZ144 is a modular endolysin with an N-terminal pepti-
doglycan binding domain and a C-terminal catalytic domain with
transglycosylase activity, encoded by bacteriophage KZ, which
infectsP. aeruginosa (25, 27).We show that anArtilysin composed
of SMAP-29 fused to KZ144 is a highly potent antibacterial that
kills virtually all P. aeruginosa strains, acts quickly (within min-
utes), is recalcitrant to resistance development, and is also able to
kill metabolically inactive persisters.
MATERIALS AND METHODS
Cloning and mutagenesis. The coding sequence for Artilysin 085 (Art-
085) was constructed by fusing the sequence of SMAP-29 (24) to the 5=
end of the open reading frame of KZ144. Therefore, the SMAP-29 gene
fragment was inserted between the NdeI and BamHI restriction sites of
pET21a (Novagen, Madison, WI) and the fragment encoding KZ144 be-
tween the BamHI and XhoI sites. For proper selection, ampicillin (100
g/ml) was used. AC-terminal His6 tag is present for affinity purification.
Three Cys residues at positions 45, 54, and 81 of Art-085 were changed to
Ser residues using the Quick Change mutagenesis (Q5 site-directed mu-
tagenesis kit; New England BioLabs, Ipswich,MA), according to theman-
ufacturer’s instructions, resulting in Art-175. The same kit was used to
change the catalytic residue of KZ144 in Art-175 (Glu115 of KZ144) to
alanine.
Recombinant expression and purification.The recombinant expres-
sion of both Artilysins was performed in 2 liters lysogeny broth (LB) with
exponentially growing Escherichia coli strain BL21(DE3) pLysS cells (op-
tical density at 600 nm [OD600], 0.45 to 0.55) upon induction with 0.5
mM isopropyl--D-thiogalactopyranoside (IPTG) at 37°C for 3 to 4 h. E.
coli cells were harvested by centrifugation (3,900 g for 30 min at 4°C),
and the obtained cell pellet was resuspended in 40 ml lysis buffer (20 mM
HEPES, 1,000 mM NaCl, 20 mM imidazole, and 1 mM MgCl2 [pH 7.4]
supplemented with 40 g DNase I). Cell disruption was done by sonica-
tion (Bandelin Sonopuls HD3200; conditions, 45% for 6 min with 10-s
pulse/20-s break steps) on ice. Cell debris was separated by centrifugation
at 15,000 g for 20 min, and the supernatant was then filtered (0.2 m)
before application to the column. Purification of the His6-tagged fusion
proteins was performed on an Aktä fast protein liquid chromatography
(FPLC) system (GE Healthcare, Little Chalfont, United Kingdom) con-
trolled byUNICORN5.1 software withNi2-charged immobilized-metal
affinity chromatography (IMAC) columns (1 ml HiPrep IMAC FF; GE
Healthcare). The proteins were bound to the column using buffer A (20
mMHEPES, 1,000mMNaCl, 20mM imidazole [pH7.4]) and elutedwith
a linear gradient to 100% buffer B (20 mM HEPES, 500 mM NaCl, 500
mM imidazole [pH 7.4]). The fractions containing the purified Artilysins
were pooled and adjusted to a concentration of approximately 0.5 mg/ml
with bufferC (20mMHEPES, 500mMNaCl [pH7.4]).Next, ammonium
sulfate was added using a 3.8 M stock solution at room temperature, with
stirring, up to 850mM.The prepared protein solutionwas added to a 5-ml
or 20-ml GE Healthcare Phe-HP Sepharose column and eluted with a
60% buffer C step (20 mM HEPES, 500 mM NaCl [pH 7.4]). After
dialysis against an appropriate buffer, the protein concentration was
determined spectrophotometrically in silica cuvettes at a wavelength
of 280 nm (Jasco V-650; Jasco Corporation, Tokyo, Japan). The endo-
toxin content of the purified Art-175 was measured with the Pyrogent
Plus LAL kit (catalog no. N294-125; sensitivity, 0.125 endotoxin unit
[EU]/ml; Lonza, Basel, Switzerland), according to the manufacturer’s
instructions, and was 0.325 EU/ml.
CD spectroscopy. To measure the melting temperature (Tm), the el-
lipticity of the proteins was recorded at 220 nm in a Jasco model J-815
circular dichroism (CD) spectrometer (Jasco Corporation). The protein
melting temperatures were determined with a heating rate of 1°C/min, an
incubation time of 3 s, and a volumeof 410l in a 1-mm light pathHellma
quartz cuvette. All measurements were performed in 50 mM sodium
phosphate buffer-300mMNaCl at pH 7.4. Themidpoint of the unfolding
transition was determined by fitting to a sigmoid unfolding model using
JASCO analysis software. The proteins were measured at concentrations
of 5.4M(Art-085) and 5.3M(Art-175). Far-UV spectrawere recorded
at protein concentrations of 5.56 M (KZ144), 5.60 M (Art-085), and
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6.25 M (Art-175) in 50 mM sodium phosphate buffer-300 mM NaCl
(pH 7.4) at a temperature of 20°C.
Thermal aggregation. The thermally induced aggregation was mea-
sured in a V-650 UV/VIS spectrometer (Jasco Corporation) with temper-
ature control. For all measurements, silica cuvettes were used, with stir-
ring. The aggregationwasmeasured at 360 nmwithin a temperature range
of 20°C to 60°C, with a constant heating rate of 0.5°C/min. The protein
concentration was 0.1 mg/ml in 20 mMHEPES-500 mM NaCl (pH 7.4).
Bacterial strains and culture conditions. The P. aeruginosa strains
used in this study were collected in the Queen Astrid Military Hospital in
Brussels, Belgium (28, 29), or provided by A. Gessner from the Institute of
Medical Microbiology University of Regensburg, Germany, P. Cornelis
from the Free University of Brussels, Belgium (strain PA14wt), F. Van
Bambeke from the Université Catholique de Louvain, Belgium, O. Denis
fromHôpital Erasme, Belgium (strain PA1255), K. Tateda from the Toho
University in Tokyo, Japan, orM. Schobert from the Technical University
of Braunschweig, Braunschweig, Germany. Other bacteria used in this
study were from DSMZ (German Collection of Microorganisms and Cell
Cultures), the Robert Koch Institute, Wernigerode, Germany (A. Fruth),
theCentre ofMicrobial andPlantGenetics, Leuven, Belgium (R.DeMot),
or A. Gessner. All strains were grown in LB, except Enterococcus faecalis,
Clostridium perfringens, and Bacteroides fragilis, which were grown in liq-
uid Reinforced Clostridial Medium (RCM) (Oxoid, Basingstoke, United
Kingdom) without shaking or on Columbia blood agar plates at 37°C. E.
faecaliswas grown under microaerophilic conditions (85%N2, 10%CO2,
5% O2). C. perfringens and B. fragilis were grown anaerobically (Anaero-
Gen [Oxoid]; oxygen level,	1% within 30 min; resulting CO2 level, 9 to
30%).
Antibacterial assay. P. aeruginosa strain PAO1 or S. aureus strain
DSM 346 was grown to the mid-exponential phase (OD600, 0.6), har-
vested by centrifugation (16,000  g for 5 min), washed, and 10-fold
diluted in 10 mMHEPES (pH 7.4) containing 0, 0.25, or 1 mM EDTA to
a final density of108 cells/ml. Fifty microliters of the bacterial cell dilu-
tion was incubated at 25°C, with shaking, with 50 l of a protein solution
containing either 10 g KZ144, Art-085, or Art-175 or 1 g of SMAP-29
(Sigma-Aldrich, St. Louis, MO) in 20mMHEPES buffer (pH 7.4). After a
60-min incubation, appropriate dilutions of the cell suspensions were
plated on LB agar in triplicate. Colonies were counted after overnight
incubation at 37°C. The antibacterial activity was quantified as the relative
inactivation in log units (log10[N0/Ni] with N0 as the initial number of
untreated cells and Ni as the number of residual cells counted after treat-
ment).
Cytotoxicity. In compliance with EN ISO 10993-5:2009, Art-175
(5.17 mg/ml in phosphate-buffered saline [PBS]-0.01% Tween 20) was
tested in vitro for cytotoxicity by Zwisler Laboratorium GmbH (Con-
stance, Germany). Therefore, L-929 mouse connective tissue fibroblasts
were cultured as a monolayer (6th split of L-929 DSM ACC2 culture,
clone of strain L). The culture medium (RPMI 1640) was supplemented
with 10% (vol/vol) fetal bovine serum (FBS), 100U/ml penicillin, and 100
g/ml streptomycin. All compounds were purchased from Life Technol-
ogies (Grand Island, NY). The sample was diluted 1:5, 1:10, 1:20, and 1:40
in cell culture medium and was incubated with the cells for 2 days. There-
after, the degree of cell destruction was evaluated using microscopy and
subsequent viability staining using the tetrazole 3-(4,5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) in a colorimetric as-
say. The suitability of the test system was confirmed by positive and neg-
ative controls. A sample with a resulting cell viability of 
90% was
considered noncytotoxic.
MIC determination. The MICs of Art-085 and Art-175 were deter-
mined by the broth microdilution method in 96-well microtiter plates.
The respective bacterial overnight culturewas diluted 1:5,000 to a concen-
tration of 2  105 to 8  105 CFU/ml in non-cation-adjusted Mueller-
Hinton (MH) broth (Difco, BD, Franklin Lakes, NJ) and split into the
required amount of wells. Reinforced Clostridial Medium (Oxoid) was
used for C. perfringens and B. fragilis. Art-085 and Art-175 were added in
different concentrations (determined as final concentration [g/ml] in
MH broth). EDTA was added to a final concentration of 0 or 0.5 mM, as
indicated in Tables S1 and S2 in the supplemental material. The MIC
assays with C. perfringens and B. fragilis were prepared in the microaero-
philic chamber prior to anaerobic incubation. The mixtures were incu-
bated overnight (18 h) at 37°C, except for P. aeruginosa strains Colja 7 (33
h), 06071 (48 h), and va32872_1 (48 h). P. aeruginosa strains BT73 and
11159 were measured after incubation for 4 days at room temperature.
Bacterial growth was determined by turbidity measurements in an en-
zyme-linked immunosorbent assay (ELISA) reader (Tecan InfiniteM 200
Pro; Tecan, Männedorf, Switzerland). All measurements were performed
in comparison to a negative control (MH broth without bacteria) or a
positive control (without Artilysin). The MIC was defined as the mini-
mumconcentration atwhichnobacterial growthwas observed in thewell.
Time-lapse microscopy. Time-lapse microscopy experiments were
performed with a temperature-controlled (Okolab, Ottaviano, Italy)
Eclipse Ti-E inverted microscope (Nikon, Champigny-sur-Marne,
France) equipped with a Ti-CT-E motorized condenser and a CoolSNAP
HQ2 FireWire CCD camera, as described previously (30). P. aeruginosa
PAO1 cells were grown to mid-exponential phase (OD600, 0.6), washed
three times with PBS (pH 7.4), and finally concentrated five times by
resuspension in PBS–0.5 mM EDTA-Na2. Art-175 was added to a final
concentration of 0.1mg/ml, corresponding to 25MIC. For imaging, the
samples were placed between PBS agar pads and a cover glass, essentially
as described previously (30), and incubated at 37°C. The time between the
addition of Art-175 to the cells and recording was kept as short as possible
(60 s). Images were acquired usingNIS-Elements (Nikon), and the result-
ing pictures were further handled with open-source software, ImageJ
(http://rsbweb.nih.gov/ij/).
Time-kill curve. Mid-exponentially growing cells (OD600, 0.6) of P.
aeruginosa PAO1 in LB medium were harvested by centrifugation
(16,000  g for 5 min), washed twice with 2.5 ml PBS (pH 7.4), and
resuspended in 1 ml PBS to a final density of109 cells/ml. A suspension
with a total volume of 800 l containing 576 l of the bacterial cell dilu-
tion, 0.5 mM EDTA-Na2 (final concentration), and 80 g Art-175 in 20
mM HEPES buffer-500 mM NaCl (pH 7.4) was prepared. This stock
solutionwas incubated at 25°Cwith shaking for the times indicated. At the
respective time points, 50 l was taken, and appropriate dilutions of the
cell suspensions were plated on LB agar in triplicate. Colonies were
counted after overnight incubation at 37°C. The antibacterial activity was
quantified as the relative inactivation in log units (log10[N0/Ni], withN0 as
the initial number of untreated cells andNi as the number of residual cells
counted after treatment).
Resistance development. The MICs of Art-175 and ciprofloxacin
(Sigma-Aldrich) against P. aeruginosa strains PAO1, Br257, and Br776
were determined. Two-fold dilution series of Art-175 were prepared in 20
mM HEPES-100 mM NaCl in a round-bottom 96-well microtiter plate
(Nunc; Thermo Fisher Scientific,Waltham,MA). The bacterial inoculum
was prepared from an 18-h Mueller-Hinton (MH) agar plate, and the
suspensionwas adjusted to reach a turbidity equivalent to a 0.5McFarland
standard (31). This suspension was further diluted 100 in 2MHme-
dium (with 1 mM EDTA-Na2 for Art-175). Fifty microliters of bacterial
suspension was mixed with 50 l Art-175 and incubated for 24 h at 37°C.
Controls with MHmedium (0.5 mM EDTA-Na2) only and MHmedium
(0.5 mM EDTA-Na2) with cells were included. On the next day, the MIC
was recorded as the minimal concentration that completely inhibited
growth. A newMIC assay was prepared using 1,000-diluted cells grown
at MIC/2 (occasionally MIC/4 if growth in MIC/2 was too limited). This
was repeated for 20 passages.
Persister killing. Planktonic persister cells were isolated from a sta-
tionary-phase culture as described previously (32), with minor modifica-
tions. An overnight culture of P. aeruginosa PA14 or PA1255 (a cystic
fibrosis isolate) was inoculated in 50 ml 1:20 Trypticase soy broth (TSB).
After 48 h of growth at 37°C, the culture was treated with ofloxacin at a
final concentration of 10 g/ml (5MIC) for 5 h at 37°C, while shaking
Briers et al.
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at 200 rpm. The persister cells surviving this antibiotic treatment were
isolated by centrifugation (5,250 g for 15min at 4°C), and the cell pellet
was washed twice with 20 mM HEPES (pH 7.4). Prior to treatment, the
cells were resuspended in the same volume of 20 mMHEPES (pH 7.4). A
persister killing assay was performed as described previously (32), with
minor modifications. A volume of 100l of the isolated persister fraction
was mixed with either Art-175 or ciprofloxacin (final concentrations of
10 or 30 MIC against the respective strains), in the absence or pres-
ence of 0.5 mM EDTA-Na2 (final concentration) up to a final volume of
200l. Control treatments with 20 mMHEPES (pH 7.4), 0.5 mMEDTA,
or ofloxacin (30 and 10 MIC) were performed in parallel. The mix-
tures were shaken (200 rpm) for 1 h at 37°C. The treated persisters were
washed twice with 20mMHEPES (pH 7.4), and the appropriate dilutions
were plated on TSB plates and incubated at 37°C. The number of persist-
ers was determined after 72 h of incubation to allow for complete resus-
citation of all surviving persisters. Each experiment was independently
repeated3 times.
RESULTS
Art-085 and its optimized Art-175 homolog efficiently kill P.
aeruginosa. Initially, the SMAP-29 peptide was fused to the N
terminus of full-length KZ144, namedArt-085. AHis6 tag at the C
terminus allowed for purification by metal affinity chromatogra-
phy. Since Art-085 forms oligomers due to (an) intermolecular
disulfide bridge(s), similar to wild-type KZ144, a triple mutant of
Art-085 was constructed by exchanging three cysteines (Cys14,
Cys23, and Cys50) of KZ144 for serine (Art-175). Circular dichr-
oism (CD) spectra show a mainly -helical composition and do
not show conformational differences among KZ144, Art-085, and
Art-175 (see Fig. S1A in the supplementalmaterial). SDS-PAGEof
reduced and nonreduced Art-085 and Art-175 (see Fig. S1B in the
supplemental material) and gel filtration chromatography con-
firm that no oligomers are present inArt-175 in contrast to nonre-
duced Art-085 (data not shown). The unfolding of Art-085 and
Art-175wasmonitored as a function of temperature bymeasuring
the ellipticity at 222 nm, an indicator for changes in helicity (see
Fig. S1C in the supplemental material). The unfolding of Art-175
occurs more cooperatively and at a significantly higher tempera-
ture (Tm 50.3°C) than that of Art-085 (Tm 44.2°C), indicating
a more stable conformation for Art-175. In addition, we analyzed
the aggregation of Art-085 and Art-175 by measuring UV absor-
bance at 360 nm with increasing temperature (see Fig. S1D in the
supplemental material). The aggregation of Art-085 starts at a
lower temperature than for Art-175, and the corresponding peak
is wider. This confirms the increased thermostability and rapid
cooperative unfolding of Art-175 (only monomer) compared to
those of Art-085 (mono- and oligomers).
We compared the antibacterial activities of 3 M SMAP-29,
KZ144, Art-085, and Art-175 against P. aeruginosa PAO1 in the
presence of 0, 0.125, or 0.5mMEDTA (Fig. 1). SMAP-29 is highly
bactericidal, with complete killing without EDTA (5.15 log
units) in 60 min. The endolysin KZ144 cannot efficiently perme-
ate the outer membrane to hydrolyze the PG layer and therefore
shows only limited antibacterial activity (0.57 0.14 log units) in
the absence of EDTA. At 125MEDTA, the bacterial reduction is
improved slightly from 0.80 0.11 log (125 M EDTA alone) to
1.52  0.04 log units. Art-085 and Art-175 have bactericidal ac-
tivities similar to that of SMAP-29, with almost complete eradica-
tion (4.66 0.20 log and 4.23 0.26 log units, respectively) in the
absence of EDTA; this is further enhanced in the presence of 125
M EDTA, resulting in complete killing (5.15 log units com-
pared to the untreated controls). Since SMAP-29 shows cytotox-
icity to mammalian cells (15), the cytotoxicity of Art-175 was an-
alyzed using L-929 mouse connective tissue fibroblasts. A sample
of 5.2 mg/ml Art-175 was tested in 1:5, 1:10, 1:20, and 1:40 dilu-
tions. After 2 days of exposure, 93% 1.4% fibroblasts were via-
ble, and nomore than 10% of the cells showed cell lysis or discrete
intracytoplasmic granules. Art-175 is therefore considered to be
noncytotoxic, in compliance with EN ISO 10993-5:2009 (see Fig.
S2 in the supplemental material).
Art-175 kills all P. aeruginosa strains, including multidrug-
resistant isolates. The MICs of Art-085 and Art-175 against P.
FIG 1 Bactericidal effects of SMAP-29, KZ144, Art-085, and Art-175 against P. aeruginosa PAO1. A cell suspension was treated with equimolar amounts of
SMAP-29, KZ144, Art-085, and Art-175 (3 M) in the absence and presence of 0.125 or 0.5 mM EDTA. Bacterial reduction after 1 h is expressed in log10 units
relative to the untreated control.Mean values ( standard deviation [SD]) are shown. An asterisk indicates when the detection limit (5.15 log units) was reached.
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aeruginosa PAO1 were 18 and 10 g/ml, respectively (Table 1).
Expressed as a molar concentration, these correspond to 0.5 and
0.3 M, respectively, which are approximately the same as those
for ciprofloxacin against the same strain (0.5 M) and endolysins
against Gram-positive pathogens (0.3 M) (34). In the presence
of EDTA, theMICs decrease in a nonlinear EDTA-dependent way
to 4 and 2 g/ml, respectively. Art-085 and Art-175 are strongly
inhibitory against all tested P. aeruginosa strains (n  74 and 79,
respectively) with an MIC50 and an MIC90 of 8 and 15 g/ml for
Art-085 and 4 and 10 g/ml for Art-175, respectively, with no
differences in susceptibility among the environmental, clinical,
and multidrug-resistant strains (see Table S1 in the supplemental
material). In fact, the growth of multidrug-resistant P. aeruginosa
strains covering resistance mechanisms to several therapeutically
used antibiotics is fully inhibited by Art-175 (see Table S2 in the
supplemental material).
The activity spectra of Art-085 and Art-175 were further ana-
lyzed on a broad panel of bacterial species, including Gram-neg-
ative organisms (Pseudomonadaceae, Enterobacteriaceae, and Bac-
teroidaceae), Gram-positive species, and a single yeast species
(Candida albicans) (see Table S3 in the supplemental material) in
the absence of EDTA. Art-085 and Art-175 showed the highest
inhibitory activities against P. aeruginosa and the plant pathogen
Pseudomonas syringae. Also, some reduced activity was observed
against the soil bacterium Pseudomonas putida. All other species
testedwere not susceptible to20g/ml Art-085 or Art-175, with
the exception of Klebsiella pneumoniae (7.5 and 10 g/ml for Art-
085 andArt-175, respectively) and Salmonella enterica serovar En-
teritidis (14 g/ml for Art-085).
Art-175 rapidly kills bacteria through cell lysis. The working
mechanism of Art-175 was visualized using time-lapse micros-
copy (see Movie S1 in the supplemental material). A concentra-
tion corresponding to 25MIC in the presence of 0.5 mMEDTA
was mixed with P. aeruginosa PAO1 cells. Within 20 min, all cells
within the microscopic field were lysed. A detailed view (Fig. 2A;
see also Movie S2 in the supplemental material) shows that com-
plete lysis wasmostly preceded by cytoplasmicmembrane bulging
through a hole created in the cell wall. When a slightly higher
concentration of Art-175 (30MIC) was added, all cells had al-
ready adopted a pleomorphic shape before recording could start
(1 min), resembling spheroplasts that lacked an intact PG sac-
culus. A complete microscopic field was cleared within 6 min. To
quantify the rapid mode of action of Art-175, a time-kill curve of
Art-175was determined under conditions identical to those of the
time-lapse series (25MIC) (Fig. 2B). In the first 5 min, a time-
dependent bactericidal effect up to an approximately 3-log reduc-
tion was observed. Between 5 and 30 min, the bacterial reduction
further increased from about 3 to 4 log units. Art-175 thus con-
serves a rapid action similar to those described for SMAP-29 and
endolysins in general (18, 35).
A similar time-lapse microscopic experiment was performed
with an equimolar amount of SMAP-29 (see Movie S3 in the sup-
plemental material). The observations, however, differ signifi-
cantly from those with Art-175: first, the cells gradually lost their
dense cellular content, as indicated by the formation of blebs on
the surface and obvious contrast reduction, but intact PG sacculi
remained and no cell lysis was observed; second, the morpholog-
ical changes were slower, with visible changes taking place during
a 1-h period; third, some unaffected cells continued to grow and
multiply. These observations correspond to the proposedmode of
action of SMAP-29, i.e., permeabilizing the outer and cytoplasmic
membrane (24). The differences between killing by Art-175 and
SMAP-29 clearly indicate a differentmode of action,with a pivotal
role for cell lysis through cell wall degradation by Art-175. These
observations are consistent with a peptide-assisted uptake of the
endolysin KZ144 through the outer membrane, followed by os-
motic lysis through PG degradation.
To analyze possible remaining bactericidal activity of the
SMAP-29 moiety through cytoplasmic membrane disruption, we
also analyzed the bactericidal activities of SMAP-29, KZ144, Art-
085, and Art-175 against S. aureus DSM 346 (see Fig. S3 in the
supplemental material). SMAP-29 has a broad antibacterial spec-
trum against bothGram-positive andGram-negative species (25),
whereas KZ144 is enzymatically active only on PG with chemo-
type A1, conserved among Gram-negative bacteria (25). The PG
of S. aureus has chemotype A3 (36) and is thus not susceptible to
KZ144 (25). Whereas SMAP-29 kills S. aureus (3.7 log units)
independently of EDTA concentration, KZ144, Art-085, and Art-
175 have no significant antibacterial activity (	0.5 log units) un-
der any conditions. This indicates that (i) the SMAP-29 moiety in
Art-085/Art-175 has lost its cytoplasmic membrane-disrupting
activity and (ii) efficient lytic activity of KZ144 is required for
successful killing by Art-085/Art-175. We also prepared an enzy-
matically inactive mutant of Art-175 by exchanging the Glu115 of
KZ144 for alanine. The antibacterial activity of thismutant against
P. aeruginosa PAO1 dropped from 4.23 0.05 to 1.97 0.06 log
units in the absence of EDTA, showing the essential role of active
KZ144 in Art-175 and possible residual activity of the SMAP-29
moiety against P. aeruginosa.
Art-175 is refractory to resistance development. Serial expo-
sure of three different P. aeruginosa strains (PAO1, a laboratory
strain of clinical origin; Br257, isolated from the environment;
Br776, a multidrug-resistant clinical isolate) to subinhibitory
doses of Art-175 did not lead to the recovery of resistant strains
after 20 passages (Fig. 3A to C). A maximum 2-fold increase of
MIC was observed for all strains. A similar experiment with cip-
rofloxacin yielded 16- and 64-fold-increased MICs for PAO1 and
Br257, respectively.Multidrug-resistant Br776, which showed ini-
tial high resistance against ciprofloxacin (16 M versus 0.5 and
0.25 M for PAO1 and Br257, respectively), showed a further
TABLE 1 MICs of Art-085 and Art-175a
EDTA concn (mM)
or parameter
MIC (g/ml) for:
Art-085 Art-175
0 18 10
0.125 20 10
0.25 16 6
0.5 10 4
1 6 4
2 4 2
4 4 2
MIC50
b 8 4
MIC90 15 10
a Art-175 (10 g/ml) has an improved inhibitory activity against P. aeruginosa PAO1
compared to that of Art-085 (18 g/ml). From 0.25 mM EDTA, MICs further decrease
to 4 and 2 g/ml for Art-085 and Art-175, respectively.
b The MICs at which growth of 50% (MIC50) or 90% (MIC90) of the isolates are
inhibited, are shown.
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4-fold increase in MIC. Art-175 is thus highly refractory to resis-
tance development.
Art-175 has a superior bactericidal effect against P. aerugi-
nosa persisters. Persisters are a subpopulation of antibiotic-toler-
ant cells and have been linked to chronic and recurrent infections
(8). The bactericidal activity of Art-175 was tested against this
dormant subpopulation (Fig. 4). Persister fractions of two differ-
ent strains (PA14 and PA1255, an isolate of a cystic fibrosis pa-
tient) were collected after 5-h exposure to 5MIC ofloxacin. The
lack of killing after further exposure of the isolated fractions to
increased ofloxacin concentrations (10 and 30 MIC) con-
firmed the persistent (antibiotic-tolerant) nature of both isolated
persister fractions. The persisters were incubated with different
concentrations of Art-175 or ciprofloxacin (10 MIC and 30
MIC) in the absence or presence of 0.5 mM EDTA. Art-175 (10
and 30 MIC) completely eradicated the remaining persisters
(approximately 5-log reduction) in the presence of 0.5 mM
EDTA, whereas similar doses of ciprofloxacin (with and without
EDTA) or 0.5 mMEDTA alone did not affect the persisters. In the
absence of EDTA, a 30-MIC dose of Art-175 reduced the per-
sister fractions of PA14 and PA1255 by 2.16 0.42 log and 4.35
1.15 log units, respectively. In summary, the overall activity of
Art-175 against these persister fractions is extremely pronounced.
DISCUSSION
To address the ongoing struggle between the emergence of antibi-
otic resistance and the lagging development of new antibiotics,
drastically novel strategies for antibacterial development are re-
quired. This is particularly true for Gram-negative pathogens,
which are protected by a largely impermeable outer membrane,
thinning out the number of potential antibacterials that are effec-
tive against them. Nevertheless, Gram-negative pathogens, such
as P. aeruginosa, are often the primary cause of chronic infections.
Artilysins feature essential properties of such a novel strategy, as
they are innovative because of the unique combination of two
novel classes of antibacterials, exert a rapid bactericidal effect, are
active on multidrug-resistant strains, are highly refractory to re-
sistance development, and kill persisters.
In spite ofmajor advances in endolysin research in recent years
(12, 18), Gram-negative pathogens have remained out of reach.
FIG 2 Rapid mode of action of Art-175. (A) P. aeruginosa PAO1 is rapidly lysed upon contact with Art-175 (25MIC). Shortly after adding Art-175, a hole is
the cell wall is punctured and the cytoplasmicmembrane increasingly bulges until the cell undergoes abrupt lysis (see alsoMovie S1 in the supplementalmaterial).
(B) A 30-min time course shows that P. aeruginosa PAO1 treated with 25MIC Art-175 is reduced by approximately 3 log units in the first 5 min, increasing to
4 log units after 30 min. Mean values ( SD) are shown.
Art-175 Kills MDR and Persistent P. aeruginosa
July 2014 Volume 58 Number 7 aac.asm.org 3779
 o
n
 April 28, 2015 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
FIG 3 Resistance development against Art-175 and ciprofloxacin. A laboratory strain of clinical origin (P. aeruginosa PAO1) (A), an environmental strain (P.
aeruginosa Br257) (B), and a multidrug-resistant strain (P. aeruginosa Br776) (C) were serially exposed to subinhibitory concentrations to select for decreased
susceptibility. Over 20 passages, the MIC of Art-175 () increased 2-fold, whereas the MIC of ciprofloxacin () increased 16- (PAO1), 64- (Br257), or 4-fold
(Br776).
Briers et al.
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Artilysins now expand the potential of endolysins to reach Gram-
negative species. The conceptual idea of Artilysins relies on a pep-
tide-assisted uptake of the endolysin moiety through the outer
membrane, followed by enzymatic degradation of the PG layer
and osmotic lysis. Our microscopic observations are consistent
with this model, showing cytosol release, followed by complete
cell lysis, in contrast to SMAP-29, which works more slowly and
does not induce lysis. This demonstrates that the endolysin must
be transferred to the periplasm due to the outer membrane-dis-
rupting capacity of the SMAP-29moiety. The bulging cytoplasmic
membrane prior to complete lysis is identical to the lytic effect of
endolysins targeting Gram-positive species (20), indicating that
local holes are created in the PG layer. The critical pore size in the
Gram-negative PG layer to initiate bulging has been calculated as
approximately 20 nm (37), meaning that only several adjacent
glycan chains have to be hydrolyzed to induce irreversible release
of the cytosol. Hence, the capacity of SMAP-29 to induce local
outer membrane disruption is conserved within the fusion pro-
tein. In contrast, the bactericidal effect of the SMAP-29 moiety
through cytoplasmic membrane permeabilization appears to be
lost or limited within the Artilysins. The inactivity of Art-175
against Gram-positive S. aureus DSM 346, from which the PG
layer is not a suitable substrate for KZ144, points to a complete
loss of this effect. However, the limited antibacterial activity of an
enzymatically inactive mutant of Art-175 may suggest some re-
maining effect of the SMAP-29 moiety against P. aeruginosa. An
alternative explanationmight be that the binding of themutant to
the PG layer upon crossing the outer membrane interferes with
PG homeostasis even without catalytic activity, resulting in lim-
ited cell death through the disturbed balance of PG degradation
and synthesis. In addition, we cannot excludeminor residual mu-
ralytic activity of the mutant due to a secondary catalytic residue,
which falls below the sensitivity of the assay.
Importantly, Art-175 lacks any cytotoxicity on L-929 mouse
connective tissue fibroblasts, an international standard cell cul-
ture line used to evaluate acute adverse biological effects (ISO
10993-5:2009). Hence, Art-175 has a high bactericidal effect but
differs from SMAP-29 and antimicrobial peptides in general,
which often show cytotoxicity to mammalian cells (15).
Alternative approaches that translocate a lytic enzyme across
the outer membrane have been reported. We have shown the ef-
ficacy of high hydrostatic pressure combined with endolysins
againstGram-negative species (approximately 4 log unitswith 200
MPa), a technique applicable as a hurdle technology in food con-
servation (38). Protein engineering-based methods rely on the
transport of T4 lysozyme via the TonB-dependent outer mem-
brane transporter FyuA through a fusion of the enzyme to the
FyuA binding domain of pesticin (39), or the modification of eu-
karyotic lysozymes with diverse peptides or chemical substituents
to increase hydrophobicity (for a review, see reference 50). Both
methods yielded fusion proteins that successfully killed Gram-
negative bacteria, but the bactericidal effect was generally limited
(	1-log reduction) compared to that of the Artilysins presented
in this study.
Art-085 and its improved homolog Art-175 have been devel-
oped to target P. aeruginosa infections. Within the family Pseu-
domonadaceae, nonhuman pathogens (P. syringae and P. putida)
are susceptible to Art-085 and Art-175 as well, but Enterobacteri-
aceae (except K. pneumoniae) are excluded. Commensal flora,
such as Staphylococcus epidermidis, S. aureus, Streptococcus pneu-
moniae (skin and nasopharynx), C. perfringens, C. albicans (skin),
B. fragilis, and E. coli (gut) are unaffected (
20 g/ml). A large
screen of inhibitory activities against a diverse panel of P. aerugi-
nosa isolates (n 79), comprising both environmental and clini-
cal strains, showed the broad applicability of both Artilysins. Clin-
ical isolates from samples from (burn) wounds, sputum of cystic
FIG 4 Persister killing by Art-175. The bactericidal effects of Art-175 at 10 and 30MIC on isolated persister fractions of P. aeruginosa PA14 (light gray) and
PA1255 (dark gray) are compared to those of ciprofloxacin at 10MIC and 30MIC, in both the absence and the presence of 0.5 mMEDTA. Controls include
0.5 mMEDTA and ofloxacin (10MIC and 30MIC). Mean values ( standard error of the mean [SEM]) are shown for at least three independent replicates.
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fibrosis patients, throat, urinary tract, and lung infections, and
otitis in dogs are all susceptible, irrespective of their source or
extent ofmultidrug resistance. TheMIC is also independent of the
relative biofilm formation capacity of a strain (data not shown). In
general, Art-175 has improved MIC50 (4 g/ml) and MIC90 (10
g/ml) values compared to those of Art-085 (8 and 15 g/ml,
respectively), most likely due to its purely monomeric form. In
addition, Art-175 has a more stable conformation and improved
thermostability.
Novel classes of antibacterials should display limited resistance
development to avoid rapid and wide distribution of resistance
against novel antibacterials in the future. Art-175meets this crite-
rion, since it features a low probability of resistance development,
in contrast to ciprofloxacin, a first-line antibiotic in health care.
Highly selective exposure to subinhibitory concentrations of Art-
175 does not elicit resistance development through genetic mod-
ifications in any of three P. aeruginosa strains tested. Similarly, no
resistance has been reported to endolysins acting on Gram-posi-
tive pathogens in experimental settings to identify such resistant
mutants (40), andmicrobial resistance against antimicrobial pep-
tides is said to be rare as well (41). In future studies, mutator
strains could be used to stress resistance development by mecha-
nisms requiring multiple mutations against antimicrobial pep-
tides, endolysins, and Artilysins (42). However, the immutable
nature of PG will certainly contribute to the refractory nature of
endolysins and Artilysins in resistance development.
In addition, drug-resistant P. aeruginosa isolates, which are
resistant against any of 21 different antibiotics tested, are suscep-
tible to Art-175 to the same extent as antibiotic-sensitive strains.
This is also true for the most resistant strains that are not suscep-
tible to 19 out of 21 antibiotics tested. Hence, existing resistance
mechanisms against those therapeutically used antibiotics do not
give cross-resistance to Art-175. Cystic fibrosis isolates undergo
physiological adaptations of their LPS structure in chronic infec-
tions, generally decreasing the net charge of LPSmolecules and the
susceptibility to cationic peptides (43). However, we did not note
a difference in susceptibility among those isolates (see Table S1 in
the supplemental material; MICs, 4 to 12 g/ml).
Unmetabolized antibiotic substances have been detected in
hospital effluents, sewage systems, manure, soil, and surface and
groundwater, andmost of thempersist in the environment. These
antimicrobials exert a selection pressure and select for resistant
mutants in resident microbial communities, particularly when
bacteria are exposed to subtherapeutic levels of the antimicrobials.
In addition, resistance genes can be transferred by horizontal
transfer (44). Due to the proteinaceous nature of Artilysins and
their consequent biodegradability, Artilysins are expected not to
persist in the environment and therefore to have a low environ-
mental impact. This property further reduces their risk of devel-
oping resistance.
Although chronic infections are primarily caused by drug-sen-
sitive pathogens, they are hard to treat with antibiotics. Persisters
are responsible for this apparent paradox. These cells constitute a
small fraction of the bacterial population that is transiently drug
tolerant without having acquired resistance through geneticmod-
ification. Instead, their insensitivity to antibiotics is mostly ex-
plained by a shutdown of metabolic processes (45). In a model of
relapsing biofilm infections (8), it has been proposed that persist-
ers hidden in the biofilm matrix are shed from the surrounding
tissue and bloodstream.Hence, these persisters are protected from
elimination by the immune system and can repopulate the biofilm
when the antibiotic concentration drops. Artilysins do not require
an active bacterial metabolism to exert their bactericidal effect, as
they actively degrade the PG layer, resulting in immediate osmotic
lysis. Unlike traditional antibiotics, Art-175 kills persisters of both
strains tested (PA14 and PA1255) in a rapid (1 h) and efficient
(from 
2 log units to complete eradication) way. Despite the
clinical relevance of persisters and their role in treatment failures
being increasingly recognized, there are currently no practical
means for eradicating them (46), or no suchmolecules have been/
are being tested in clinical trials (see clinicaltrialsregister.eu and
clinicaltrials.gov). Current developments of antipersister thera-
pies focus on screening large libraries to identify molecules that
kill persisters (47), the resuscitation of dormant persisters to re-
sensitize them to conventional antibiotics (48), or the prevention/
reduction of persister formation (45). Treatment with the Trp-/
Arg-containing peptide (RW)4-NH2 reduced viable E. coli
persister cells by 2.5 log units in 30 min; however, a higher con-
centration of (RW)4-NH2 (80 M) was needed than that needed
for Art-175 (1.2 to 3.6M) (32). Art-175 thus shows promise not
only for killing of metabolically active vegetative cells but also as a
potential treatment option for chronic infections caused by ever-
repopulating persisters surviving antibiotic treatment, e.g., in cys-
tic fibrosis (CF) patients. The majority of CF patients succumb to
chronic lung infections caused by P. aeruginosa, such as the
PA1255 strain used in this study, and the recalcitrance of CF in-
fections has been linked to an increased level of persister forma-
tion, particularly in isolates recovered during the late stages of
infection (49). Art-175 inhibits the growth of all cystic fibrosis
isolates tested (see Table S1 in the supplemental material), has a
low probability of developing resistance, and kills both replicating
and nonreplicating P. aeruginosa cells. Art-175 is thus well suited
for further development to protect or treat chronically infectedCF
patients.
In summary, Artilysins represent a class of novel antibacterials
that expand the applicability of endolysins to include Gram-neg-
ative species by merging the benefits of an antimicrobial peptide
and a highly active endolysin. Art-175 combines superior features,
as it has a quick onset of action, low risk for developing resistance,
expected low environmental impact, and bactericidal activity
against both drug-resistant strains and persisters. Therefore, Art-
175 holds promise in a wide range of applications in hygiene and
veterinary and human medicine, with a special emphasis on
chronic infections (in human medicine), such as cystic fibrosis-
associated lung infections.
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